Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of Zagociguat in Participants With MELAS (PRIZM)

NCT06402123 is registered in ClinicalTrials.gov with Tisento Therapeutics as lead sponsor.

NCT NCT06402123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06402123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b Randomized, Double-blind, Placebo-controlled Crossover Study Evaluating the Efficacy and Safety of Zagociguat in Participants With MELAS (PRIZM)
Lead sponsor
Tisento Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
September 10, 2024
Completion date
June 29, 2026
Enrollment
43 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (melas syndrome)